Bagsværd, Denmark, 18 December 2024 — Today, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The completion follows the finalisation of Novo Holdings’ acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US).
The agreement to acquire the three manufacturing sites was announced on 5 February 2024. For further information, please see the company announcement here.
“We are very pleased with the completion of the acquisition. The three sites will expand our manufacturing capacity at scale and speed, while complementing our ongoing significant internal supply chain expansions. The acquisition will enable us to reach significantly more people living with serious chronic diseases,” said Lars Fruergaard Jørgensen, president and chief executive officer of Novo Nordisk.
The expected financial impacts of the acquisition in 2024 and 2025 were disclosed on 14 December 2024. For further information, please see the company announcement here.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
Ambre James-Brown | Liz Skrbkova (US) |
| Investors: | |
Jacob Martin Wiborg Rode | David Heiberg Landsted |
Sina Meyer | Ida Schaap Melvold |
Frederik Taylor Pitter (US) |
Company announcement No 98 / 2024
Attachment
